Ticker League

Latest period

$101.64M

YoY change

+14.3%

5Y CAGR

+9.8%

Peak year (2025)

$91.66M

Stock-Based Compensation history chart for ResMed (RMD) from 1993 to 2025

Latest: $91.66M

Stock-Based Compensation growth chart for ResMed (RMD) from 1993 to 2025

Latest: +14.3%

Stock-Based Compensation history table for ResMed (RMD) from 1993 to 2025

  • 2025$91.66M+14.3%
  • 2024$80.18M+12.7%
  • 2023$71.14M+9.0%
  • 2022$65.26M+2.1%
  • 2021$63.93M+11.1%
  • 2020$57.56M+10.5%
  • 2019$52.07M+7.6%
  • 2018$48.41M+5.4%
  • 2017$45.92M-1.0%
  • 2016$46.41M-3.0%
  • 2015$47.85M+10.1%
  • 2014$43.46M+13.9%
  • 2013$38.16M+24.8%
  • 2012$30.59M-0.7%
  • 2011$30.81M+3.6%
  • 2010$29.73M+16.5%
  • 2009$25.52M
  • 2008$0.00
  • 2007$0.00
  • 2006$0.00
  • 2005$0.00
  • 2004$0.00
  • 2003$0.00
  • 2002$0.00
  • 2001$0.00
  • 2000$0.00
  • 1999$0.00
  • 1998$0.00
  • 1997$0.00
  • 1996$0.00
  • 1995$0.00
  • 1994$0.00
  • 1993$0.00

Stock-Based Compensation values are taken from ResMed's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Stock-Based Compensation at ResMed (RMD)

Stock-Based Compensation for ResMed (RMD): headline value $101.64M · YoY +14.3%. Annual and quarterly series, chart, and tables are below.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

As of the 2025 fiscal year, ResMed (RMD) reported stock-based compensation of $91.66M – grew 14.3% year-over-year.

Through 2020–2025 (5 years), ResMed stock-based compensation delivered a +9.8% annualised rate; with mixed annual results across the window.

Across the available history, stock-based compensation reached its high of $91.66M in 2025 and its low of $0.00 in 1993.

ResMed Stock-Based Compensation by Year

ResMed Stock-Based Compensation 2025: $91.66M

ResMed stock-based compensation in 2025 was $91.66M, grew 14.3% from 2024. This figure represents the highest annual value in the available history.

ResMed Stock-Based Compensation 2024: $80.18M

2024's stock-based compensation for ResMed came in at $80.18M, grew 12.7% from 2023.

ResMed Stock-Based Compensation 2023: $71.14M

ResMed posted stock-based compensation of $71.14M in 2023, grew 9.0% from 2022.

ResMed Stock-Based Compensation 2022: $65.26M

In 2022, ResMed reported stock-based compensation of $65.26M, edged up 2.1% from 2021.

ResMed Stock-Based Compensation 2021: $63.93M

ResMed stock-based compensation in 2021 was $63.93M.

See more financial history for ResMed (RMD).

Sector peers by Stock-Based Compensation

Healthcare peers of ResMed (RMD), ranked by their latest stock-based compensation

Frequently asked questions